In vitro, flow-stimulated invasion was mitigated by both blocking the receptor CXCR4 as well as saturating the ligand CXCL12, suggesting this chemokine-receptor pathway plays a key role in glioma cell flow response. Here, CXCR4 is linked to central nervous system cancer.